ArticleFrontiers in neurology
Intervention effects of different brands of botulinum toxin type A on Meige syndrome with anxiety symptoms.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with Meige syndrome are often affected by anxiety symptoms, and drug therapy is the primary treatment option, with botulinum toxin A being the most frequently used medication. This study analyzes the intervention effects of different brands of botulinum toxin A on Meige syndrome with anxiety symptoms. The findings aim to provide a theoretical basis for the rational selection of clinical treatment options. Methods: A retrospective analysis was conducted on 148 patients treated between January 2021 and December 2023. Patients were divided into two groups based on the BoNT-A brand received: Chinese botulinum toxin type A (Hengli) group ( Results: There were no statistically significant differences in the total remission rate and efficacy maintenance time between the two groups ( Conclusion: Local injection of botulinum toxin type A is a safe and effective treatment for Meige syndrome with anxiety symptoms, and there is no significant difference in the efficacy, duration of action, and improvements in psychological state and sleep quality between different brands of botulinum toxin type A. Therefore, clinical practice should be based on practical considerations to reasonably select the appropriate brand of botulinum toxin type A for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.